LOXO-292; CAS 2152628-33-4 is a selective RET inhibitor that has shown efficacy in preclinical models in treating advanced or metastatic solid tumors.



Fountainbridge’s network of suppliers allows us to supply a wide range of pharmaceutical intermediates on kg-Mt scale. We are able to supply the products below, please Contact Us for a quotation for these or any other products of interest.